Technical analysis of Puma Biotechnology, Inc. (PBYI): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine.
Price Performance
| 1 month | +1.62% |
| 3 months | +24.21% |
| Year-to-date | +57.82% |
| 1 year | +116.36% |
| 3 years | +211.96% |
| 5 years | +36.09% |
52-Week Range
| 52-week High | $9.74 |
| 52-week Low | $4.30 |
| Avg Volume (90d) | 310K |
Technical Indicators
| SMA 50 | $8.68 |
| SMA 200 | $7.21 |
| Beta | 1.18 |
| 30-day Volatility (annualised) | 42.3% |
| Price vs SMA 50 | +8.2% |
| Price vs SMA 200 | +30.2% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $5.10 | |
| 2025-11 | $5.05 | -1.0% |
| 2025-12 | $5.95 | +17.8% |
| 2026-01 | $6.48 | +8.9% |
| 2026-02 | $5.70 | -12.0% |
| 2026-03 | $6.39 | +12.1% |
| 2026-04 | $7.51 | +17.5% |
| 2026-05 | $7.17 | -4.5% |
| 2026-06 | $8.11 | +13.1% |
| 2026-07 | $7.93 | -2.2% |
| 2026-08 | $9.11 | +14.9% |
| 2026-09 | $9.39 | +3.1% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $9.39 |
| Market Cap | $478M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 16.72 |
| Price / Book | 3.30 |
| EV / EBITDA | 9.07 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.03 |
| Current Ratio | 2.91 |
| Piotroski F-Score | 7 |
| Altman Z-Score | -4.16 |